The Entourage Effect: How Cannabinoids and Terpenes Work Together

People experience cannabis in different ways, partly because the plant makes over 100 phytocannabinoids and more than 200 terpenoids, which give it its smell. The entourage effect is the idea that these compounds might work together to create effects that are different from what any single compound can do. Researchers still debate this idea, and it is often misunderstood in the CBD market.

This article looks at research on the entourage effect up to March 2026. It explains where the idea came from, reviews what science has found so far and its limits, and discusses what this means for people in Europe who use full-spectrum CBD products.

What Is the Entourage Effect?

The term “entourage effect” was first introduced in 1998 by a team led by Shimon Ben-Shabat and Raphael Mechoulam. In a study published in the European Journal of Pharmacology, they observed that certain inactive compounds in the body’s own endocannabinoid system appeared to enhance the activity of the primary endocannabinoid, 2-arachidonoylglycerol (Ben-Shabat et al., 1998). These inactive compounds did not produce effects on their own, but when present alongside the active molecule, the overall biological response changed.

In 1999, Mechoulam and Ben-Shabat updated the idea, suggesting that the way plant compounds work together could explain why whole plants act differently than extracts. They offered this as a way to guide research, not as a proven fact.

In 2011, Ethan Russo reviewed the entourage effect in the British Journal of Pharmacology. He analysed phytocannabinoids and terpenoids and suggested certain combinations might act synergistically in pain, inflammation, anxiety, and infection (Russo, 2011).

Four Proposed Mechanisms of Synergy

Wagner and Ulrich-Merzenich, in 2009, outlined four possible ways in which plant compounds could work together, using cannabis as an example (Phytomedicine). The four are: multi-target effects (compounds acting on different receptors at once), pharmacokinetic interactions (one compound improving the absorption of another), bacterial resistance modulation (combinations overcoming microbial defences), and adverse event modulation (one compound reducing the side effects of another — most relevant to the CBD/THC relationship).

These four ways that plant compounds might work together are still just theories when it comes to cannabis. Each one needs to be tested and confirmed by separate experiments.

How Do Cannabinoids and Terpenes Interact?

Phytocannabinoids and terpenoids both come from the same place in cannabis. They are made in special cells inside tiny structures called glandular trichomes, found on unfertilized female flowers. Both start from a compound called geranyl pyrophosphate, which then splits into separate paths to make cannabinoids and terpenoids (Russo, 2011). This shared biosynthetic origin is part of why researchers think they may interact.

Because of this, different cannabis chemotypes — varieties defined by their chemical profile rather than their botanical name — naturally make both cannabinoids and terpenes in different amounts. The plant’s genetics mostly decide these amounts, but things like light and soil also play a role.

Key Phytocannabinoids at a Glance

Beyond THC, several phytocannabinoids have drawn research interest. Cannabidiol (CBD) is the most studied: a 2011 review noted its versatile pharmacology, including observations of analgesic, neuroprotective, and anticonvulsant properties in preclinical models, as well as a notable ability to modulate THC-associated adverse events such as anxiety and tachycardia (Russo and Guy, 2006; Russo, 2011). CBD does not produce intoxicating effects.

Cannabigerol (CBG) is the precursor compound from which other phytocannabinoids are synthesised. Early research noted analgesic and anti-erythemic properties, and a 2008 study published in the Journal of Natural Products found that CBG demonstrated activity against methicillin-resistant Staphylococcus aureus (MRSA) at low concentrations (Appendino et al., 2008). Cannabichromene (CBC) showed anti-inflammatory activity in older studies and was identified as a strong anandamide uptake inhibitor (De Petrocellis et al., 2011). Tetrahydrocannabivarin (THCV), a propyl analogue of THC, demonstrated anticonvulsant properties in rodent models (Hill et al., 2010).

Most of what we know comes from studies done before testing in humans. There are still only a few human trials that look at cannabinoids other than THC and CBD.

The Role of Terpenes

Cannabis has more than 200 terpenoids, but most are found only in tiny amounts. In his 2011 review, Russo pointed out eight terpenes with strong scientific data: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol, and phytol.

A 1993 study in Planta Medica showed that linalool reduced movement in mice by 73% at very low levels in the blood (Buchbauer et al., 1993). In 2008, a study published in the Proceedings of the National Academy of Sciences found that β-caryophyllene acts as a full agonist at the CB2 cannabinoid receptor at 100 nM — making it the first phytocannabinoid found outside the cannabis genus (Gertsch et al., 2008). This kind of phytocannabinoid-terpenoid synergy is central to the entourage hypothesis.

Key Cannabis Terpenes: At a Glance

All eight terpenes highlighted in Russo’s 2011 review are listed below, each with their primary botanical source, receptor targets, and key study findings.

All the terpenes mentioned here are considered Generally Recognised as Safe (GRAS). Still, results from early studies may not always apply to people.

What Evidence Supports the Entourage Effect?

There is some promising evidence for the entourage effect, but there are also big gaps in what we know. The CBD industry often makes stronger claims about the entourage effect than the science currently supports.

Supporting Research

Some of the earliest suggestive evidence came from a 1974 study published in Psychopharmacologia, in which cannabis extracts demonstrated effects two to four times greater than equivalent doses of pure THC in mouse behavioural models (Carlini et al., 1974). This suggested that other compounds present in the extract were contributing to, or amplifying, the observed activity.

A 2009 study published in Fitoterapia provided a more specific comparison: a CBD-rich extract produced greater anti-hyperalgesia (reduced pain sensitivity) in a rat model than an equivalent dose of pure CBD, with additional improvements in thermal perception and nerve growth factor levels (Comelli et al., 2009). This is one of the few studies directly comparing a whole extract to its primary isolated compound.

Perhaps the most clinically significant evidence came from a human trial. A 2010 study published in the Journal of Pain and Symptom Management tested a THC:CBD extract (nabiximols) against a high-THC extract and placebo in cancer pain patients unresponsive to opioids. The THC:CBD combination achieved a statistically significant 30% pain reduction from baseline, while the THC-only extract did not distinguish from placebo (Johnson et al., 2010).

A 2018 meta-analysis published in Frontiers in Neurology examined observational data from 670 patients with treatment-resistant epilepsy and found that CBD-rich cannabis extracts produced comparable reductions in seizure frequency at a mean dose of 6.0 mg/kg/day, compared to 25.3 mg/kg/day required for purified CBD (Pamplona et al., 2018).

In 2019, Russo revisited and extended the entourage argument in a perspective article published in Frontiers in Plant Science, arguing that the cumulative evidence for cannabis synergy had grown sufficiently strong to suggest that single-molecule approaches are unlikely to replicate the therapeutic range of the whole plant (Russo, 2019). The article also proposed the term chemovar — chemical variety — as the appropriate designation for cannabis types characterised by specific cannabinoid and terpenoid profiles.

Is the Entourage Effect Proven or a Myth?

Not all studies support the entourage hypothesis, and intellectual honesty requires acknowledging this. A 2002 study found no observable difference when humans ingested or smoked pure THC versus herbal cannabis (Wachtel et al., 2002). A 2005 mouse study concluded that THC alone appeared to account for all tetrad-type effects (Varvel et al., 2005). A third study found that cannabis with varying levels of CBD or CBC content failed to produce subjective differences when combined with THC (Ilan et al., 2005).

Russo addressed these findings directly in his review. He noted that the cannabis used in the Wachtel study contained only 2.11% THC with just 0.05% CBD — concentrations he considered too low for meaningful interaction. Additionally, government-supplied research cannabis was shown to contain terpenoid concentrations four to eight times lower than commercially available cannabis (Bloor et al., 2008), potentially undermining experiments relying on these materials.

The biggest limitation is in the research methods. Russo’s 2011 review is a narrative synthesis — not a systematic review or meta-analysis. Most of the evidence comes from early-stage research, and large human trials testing specific combinations of cannabinoids and terpenes have not been done yet.

A 2024 narrative scoping review published in Cannabis and Cannabinoid Research by Simei et al. concluded that claims of clinical efficacy for cannabinoid-based products should not be built on the entourage hypothesis until dedicated clinical trials have been completed (Simei et al., 2024).

The Entourage Effect and Full Spectrum CBD Products

The entourage hypothesis is the primary scientific rationale behind consumer interest in full spectrum CBD products — extracts that retain the plant’s naturally occurring range of cannabinoids, terpenes, and other compounds, as opposed to CBD isolate, which contains only purified cannabidiol.

No CBD product has shown an entourage effect in human clinical trials. When choosing a product, consider your own tolerance, the type of extract, legal status, and advice from your healthcare provider.

Full Spectrum CBD vs CBD Isolate: Which Is Better?

There is no single answer — it depends on your goals, tolerance, and local regulations. Each of the three main extract types has a different cannabinoid and terpene profile. The table below summarises the key differences to help you understand what you are buying.

Note: THC thresholds and legal status vary across EU member states. Always verify local regulations before purchasing. No extract type has received EFSA authorization for health claims.

What Does This Mean for Consumers in Europe?

European consumers encounter the term “entourage effect” frequently in CBD product marketing. It is worth understanding both its scientific grounding and its regulatory implications.

Under EU regulations, no consumer CBD product may legally claim to produce specific health benefits. A product label stating “entourage effect for better relaxation” or “full spectrum for anxiety relief” would constitute an unauthorised health claim under EC Regulation 1924/2006, regardless of the underlying research.

Consumers should be cautious about marketing claims and know the difference between a scientific idea and a proven benefit.

Frequently Asked Questions

Sources and Further Reading

• Russo, E.B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
• Ben-Shabat, S. et al. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353(1), 23–31.
• Gertsch, J. et al. (2008). Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences, 105(26), 9099–9104.
• Johnson, J.R. et al. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract in cancer pain. Journal of Pain and Symptom Management, 39(2), 167–179.
• Wagner, H. and Ulrich-Merzenich, G. (2009). Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine, 16(2–3), 97–110.
• Carlini, E.A. et al. (1974). Effects of marihuana in laboratory animals and in man. Psychopharmacologia, 40, 195–219.
• Comelli, F. et al. (2009). Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain. Fitoterapia, 79(3), 174–181.
• Buchbauer, G. et al. (1993). Fragrance compounds and essential oils with sedative effects upon inhalation. Planta Medica, 59(6), 540–543.
• Appendino, G. et al. (2008). Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. Journal of Natural Products, 71(8), 1427–1430.
• European Medicines Agency — Epidyolex (cannabidiol) authorization.
• European Commission — EU Novel Food Catalogue.
• Pamplona, F.A., da Silva, L.R., and Coan, A.C. (2018). Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy. Frontiers in Neurology, 9:759.
• Russo, E.B. (2019). The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis. Frontiers in Plant Science, 9:1969.
• Simei, J.L.Q. et al. (2024). Does the “Entourage Effect” in Cannabinoids Exist? A Narrative Scoping Review. Cannabis and Cannabinoid Research, 9(5), 1202–1216.